1.452
price up icon1.75%   0.022
after-market Handel nachbörslich: 1.45 -0.002 -0.14%
loading
Schlusskurs vom Vortag:
$1.43
Offen:
$1.45
24-Stunden-Volumen:
578.23K
Relative Volume:
0.70
Marktkapitalisierung:
$72.13M
Einnahmen:
$300.00K
Nettoeinkommen (Verlust:
$-27.61M
KGV:
-2.5134
EPS:
-0.5777
Netto-Cashflow:
$-22.17M
1W Leistung:
+3.93%
1M Leistung:
+5.43%
6M Leistung:
-36.46%
1J Leistung:
+96.30%
1-Tages-Spanne:
Value
$1.4226
$1.475
1-Wochen-Bereich:
Value
$1.34
$1.54
52-Wochen-Spanne:
Value
$0.67
$3.82

iBio Inc Stock (IBIO) Company Profile

Name
Firmenname
iBio Inc
Name
Telefon
302-355-0650
Name
Adresse
600 Madison Avenue, Suite 1601, New York, NY
Name
Mitarbeiter
54
Name
Twitter
Name
Nächster Verdiensttermin
2026-09-04
Name
Neueste SEC-Einreichungen
Name
IBIO's Discussions on Twitter

Compare IBIO vs VRTX, REGN, ARGX, RVMD, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
IBIO icon
IBIO
iBio Inc
1.452 71.04M 300.00K -27.61M -22.17M -0.5777
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
515.57 128.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
805.86 82.72B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
986.80 53.26B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
211.94 43.66B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
362.66 39.31B 5.76B 514.49M 1.10B 4.4813

iBio Inc Stock (IBIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-06-08 Eingeleitet Raymond James Outperform
2026-06-05 Eingeleitet B. Riley Securities Buy
2025-10-21 Eingeleitet Oppenheimer Outperform
2025-10-17 Eingeleitet Leerink Partners Outperform
2024-05-28 Eingeleitet Chardan Capital Markets Buy
2021-11-29 Eingeleitet JMP Securities Mkt Outperform
2021-01-22 Eingeleitet Cantor Fitzgerald Overweight
2020-06-26 Eingeleitet Alliance Global Partners Buy
Alle ansehen

iBio Inc Aktie (IBIO) Neueste Nachrichten

pulisher
Aug 15, 2026

iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen - marketbeat.com

Aug 15, 2026
pulisher
Aug 14, 2026

Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Cormorant Asset Management (IBIO) discloses 9.99% iBio stake via stock and warrants - Stock Titan

Aug 14, 2026
pulisher
Aug 13, 2026

Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio - Stock Titan

Aug 13, 2026
pulisher
Aug 10, 2026

iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 10, 2026
pulisher
Aug 09, 2026

iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts - marketbeat.com

Aug 09, 2026
pulisher
Aug 07, 2026

iBio Inc (IBIO) Stock News Today - TradingKey

Aug 07, 2026
pulisher
Aug 06, 2026

NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView

Aug 06, 2026
pulisher
Aug 05, 2026

iBio Appoints Molly Carr as Chief Medical Officer - The Globe and Mail

Aug 05, 2026
pulisher
Aug 05, 2026

iBio Expands Must-have Cardiometabolic and Obesity Pipeline Investor through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - Diario AS

Aug 05, 2026
pulisher
Aug 04, 2026

IBIO 8-K & SEC Filings - Yahoo Finance

Aug 04, 2026
pulisher
Aug 04, 2026

iBio Inc. (IBIO) Edges Higher by 2.82% as Shares Test Key Resistance ZoneATR Trailing Stop - dars.gov.et

Aug 04, 2026
pulisher
Aug 04, 2026

iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer - Stock Titan

Aug 04, 2026
pulisher
Aug 04, 2026

iBio appoints Molly Carr as chief medical officer By Investing.com - Investing.com India

Aug 04, 2026
pulisher
Aug 04, 2026

iBio appoints Molly Carr as chief medical officer - Investing.com

Aug 04, 2026
pulisher
Aug 04, 2026

Molly Carr named Chief Medical Officer at iBio - TradingView

Aug 04, 2026
pulisher
Aug 04, 2026

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Yahoo Finance

Aug 04, 2026
pulisher
Jul 28, 2026

iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 28, 2026
pulisher
Jul 27, 2026

iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

iBio Inc (IBIO) Balance Sheet - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

iBio Inc (IBIO) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

IBIO|iBio Inc|Price:1.385|Chg%:-0.065 - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

IBIO Q2 2026 Earnings: Narrower Loss Beats Estimates; Pre-Revenue Status Remains ClearGuidance Accuracy Score - po-news-eg.net

Jul 25, 2026
pulisher
Jul 25, 2026

iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0 - TradingView

Jul 25, 2026
pulisher
Jul 25, 2026

TradingKey - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO - MarketBeat

Jul 25, 2026
pulisher
Jul 24, 2026

IBIO|iBio Inc|Price:1.430|Chg%:+0.030 - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

iBio Inc (IBIO) Institutional Confidence - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

iBio Inc. (IBIO) Slips 1.09% as Biotech Sector Faces Headwinds – Key Support at $1.29 in FocusUndervalued Stocks - dars.gov.et

Jul 23, 2026
pulisher
Jul 22, 2026

Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛

Jul 22, 2026
pulisher
Jul 18, 2026

iBio Updates Governance Deadlines for 2026 Annual Meeting - The Globe and Mail

Jul 18, 2026
pulisher
Jul 17, 2026

iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines - Stock Titan

Jul 17, 2026
pulisher
Jul 15, 2026

iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Jul 15, 2026
pulisher
Jul 12, 2026

iBio (NASDAQ:IBIO) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Jul 12, 2026
pulisher
Jul 10, 2026

iBio Inc. Holds Steady at $1.51 as Biotech Stock Consolidates Near Key LevelsSupply Zone - dars.gov.et

Jul 10, 2026
pulisher
Jul 09, 2026

We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth - Sahm

Jul 09, 2026
pulisher
Jul 08, 2026

iBio Inc. (IBIO) Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre‑Revenue PhaseBanking Earnings Report - DonanımHaber

Jul 08, 2026
pulisher
Jul 07, 2026

iBio Inc. (IBIO) Retreats 1.85%, Approaching Key Support at $1.51Narrow Range Breakout - DonanımHaber

Jul 07, 2026
pulisher
Jul 05, 2026

Price to sales forward of iBio, Inc. – NASDAQ:IBIO - TradingView

Jul 05, 2026
pulisher
Jul 03, 2026

Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail

Jul 03, 2026
pulisher
Jul 03, 2026

IBIO Maintained by Chardan Capital -- Price Target Stays at $5.0 - GuruFocus

Jul 03, 2026
pulisher
Jul 02, 2026

IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill

Jul 02, 2026
pulisher
Jul 02, 2026

IBIOiBio Inc Latest SEC Filings - Finviz

Jul 02, 2026
pulisher
Jul 01, 2026

$IBIO stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

Jul 01, 2026
pulisher
Jul 01, 2026

iBio’s IBIO-610 Antibody Achieves 98% Activin E Inhibition and Boosts Fat Loss in Obese Primates, Outperforming Semaglutide Alone 1 - Minichart

Jul 01, 2026
pulisher
Jul 01, 2026

iBio Highlights Promising New Preclinical Obesity Antibody Data - TipRanks

Jul 01, 2026

Finanzdaten der iBio Inc-Aktie (IBIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

iBio Inc-Aktie (IBIO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Duran Felipe
Chief Financial Officer
Mar 19 '26
Buy
2.02
24,835
50,132
35,974
Brenner Martin
See Remarks
Mar 19 '26
Buy
2.02
12,336
24,919
30,652
$64.45
price up icon 2.20%
$36.23
price down icon 0.07%
$59.46
price up icon 1.21%
$128.31
price up icon 3.20%
$224.60
price down icon 1.62%
ONC ONC
$362.66
price up icon 4.27%
Kapitalisierung:     |  Volumen (24h):